Neoadjuvant and Adjuvant Chemotherapy Treatment Patterns Among Older Triple-negative and HER2-positive Breast Cancer Patients with Comorbidities

被引：0
|
作者：
Tamirisa, Nina [1 ]
Dong, Wenli [1 ]
Shen, Yu [1 ]
Shaitelman, Simona [1 ]
Babiera, Gildy [1 ]
Bedrosian, Isabelle [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387856
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [11] The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review
    Wankhade, Dhanashree
    Gharde, Pankaj
    Dutta, Sushmita
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [12] Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer
    Stover, Daniel G.
    Bell, Caitlin F.
    Tolaney, Sara M.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (03) : 6 - 12
  • [13] Is nodal staging necessary for older patients with HER2-positive or triple-negative breast cancers?
    McDonough, Leslie
    Petersen, Lindsay
    Lehrberg, Anna
    Bensenhaver, Jessica
    Qutob, Omar
    Susick, Laura
    Ekkel, Elisabeth
    Thaker, Hemi
    Schwartz, Theresa
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 1) : 305 - 305
  • [14] Neoadjuvant therapy for triple negative and HER2-positive early breast cancer
    Harbeck, Nadia
    Gluz, Oleg
    BREAST, 2017, 34 : S99 - S103
  • [15] Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
    Ciriaco, Nikaoly
    Zamora, Esther
    Escriva-de-Romani, Santiago
    Gomez, Ignacio Miranda
    Flores, Jose Jimenez
    Saura, Cristina
    Sloane, Hillary
    Starus, Anna
    Fredebohm, Johannes
    Georgieva, Lucy
    Speight, Graham
    Jones, Frederick
    Ramon y Cajal, Santiago
    Espinosa-Bravo, Martin
    Peg, Vicente
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [16] Clearance of ctDNA in triple-negative and Her2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response
    Ciriaco, Nikaoly
    Zamora, Esther
    Escriva, Santiago
    Somoza, Rosa
    Hernandez-Losa, Javier
    Ramon y Cajal, Santiago
    Espinosa-Bravo, Martin
    Peg, Vicente
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 100 - 100
  • [17] New Treatment Options in ER-Positive, HER2-Positive and Triple-Negative Breast Cancer
    Steger, Guenther
    Bell, Richard
    Cameron, David
    Dent, Rebecca A.
    Jackisch, Christian
    BREAST CARE, 2013, 8 (02) : 155 - 157
  • [18] Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers
    Sousa, B.
    Cardoso, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 237 - 242
  • [19] Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer
    Clavarezza, Matteo
    Venturini, Marco
    ONCOLOGY, 2009, 77 : 14 - 17
  • [20] Updates in HER2-Positive and Triple-Negative Breast Cancers
    Telli, Melinda L.
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 605 - 609
12345